Translational Research In Oncology

[{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase III","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Translational Research In Oncology \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Translational Research In Oncology \/ Bayer AG"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Translational Research In Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Translational Research In Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bayer AG | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endotheli","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Bayer AG | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Bayer AG | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Effector Therapeutics | Stand Up To Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"MAP kinase-interacting serine\/threonine-protein kinase 1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Translational Research In Oncology \/ Effector Therapeutics | Stand Up To Cancer","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Effector Therapeutics | Stand Up To Cancer"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"UCT-03-008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-ADC","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-MAB","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-3-600","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-4-500","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"}]